Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type
| Autor: | Mendels J, Pomara N, LeWitt P, Fakouhi Jd, Herting Rl, Barry Reisberg, Stacy Skare, Dysken Mw, Wood J |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Male
medicine.medical_specialty Monoamine Oxidase Inhibitors medicine.medical_treatment Placebo-controlled study Placebo law.invention chemistry.chemical_compound Degenerative disease Randomized controlled trial Double-Blind Method law Alzheimer Disease Internal medicine Acetamides medicine Humans Psychiatry Aged Aged 80 and over Chemotherapy Psychological Tests Milacemide business.industry Cognition Middle Aged medicine.disease chemistry Female Geriatrics and Gerontology Alzheimer's disease business |
| Zdroj: | Journal of the American Geriatrics Society. 40(5) |
| ISSN: | 0002-8614 |
| Popis: | Objective Milacemide, a MAO-B inhibitor that is also a prodrug for glycine, was tested as a treatment for senile dementia of the Alzheimer type (SDAT) because of its potential for enhancing cognition in animal models of impaired learning and memory. Design Double-blind, placebo-controlled, randomized clinical trial. Setting Sixteen study sites, both university-affiliated and private. Patients A total of 228 outpatients (116 men and 112 women) with SDAT, ranging in age from 49–93 years. Intervention: 1200 mg/day milacemide treatment for 1 month (113 patients received milacemide, and 115 patients received placebo). Main Outcome Measures Alzheimer's Disease Assessment Scale and the Mini-Mental State Examination. Results Milacemide-treated SDAT patients did not show significant improvement in any of the outcome measures used. Significant elevations in liver enzymes in four subjects were of sufficient magnitude to necessitate withdrawal from the study. Conclusions Milacemide does not appear to be an effective treatment in enhanci g cognition in SDAT patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text